Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented strong financial performance with record revenues and improved net income, which is positive. However, concerns about regulatory risks, generic competition, and economic pressures in the dialysis market were highlighted, which could impact future growth. The Q&A revealed uncertainties about trial timelines and competitive dynamics. Despite positive earnings, these risks and uncertainties balance the sentiment, leading to a neutral prediction for the stock price over the next two weeks.
Key Financial Performance
Vafseo revenue $13 million in Q2, with approximately $12 million in demand sales, a 55% increase over Q1. The increase is attributed to the successful launch and growing demand.
Net product revenue Over $60 million in Q2, the highest level in the company's history. This includes contributions from both Vafseo and Auryxia.
Total revenues $62.5 million in Q2, compared to $43.6 million in Q2 of the previous year, representing an increase of $18.9 million. The growth is driven by Vafseo sales and an increase in Auryxia sales.
Auryxia sales $47.2 million in Q2, compared to $41.2 million in Q2 of the previous year. The increase is attributed to strong performance despite the loss of IP exclusivity.
Cost of goods sold (COGS) Decreased to $9.9 million in Q2, compared to $17 million in Q2 of the previous year. The decrease is due to the absence of a $9 million noncash amortization charge related to Auryxia and the use of prelaunch inventory for Vafseo sales.
R&D expenses Increased to $11 million in Q2, compared to $7.6 million in Q2 of the previous year. The increase is due to higher clinical trial activities related to Vafseo and other programs.
SG&A expenses Decreased slightly to $26.6 million in Q2, compared to $26.9 million in Q2 of the previous year.
Net income $247,000 in Q2, compared to a net loss of $8.6 million in Q2 of the previous year. The improvement is driven by increased revenues, partially offset by interest and noncash expenses.
Cash and cash equivalents $137.3 million at the end of Q2. The company believes this is sufficient to fund its current operating plan to profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Vafseo revenue: Generated over $13 million in Q2, with approximately $12 million in demand sales, a 55% increase over Q1.
Auryxia revenue: Achieved $47.2 million in sales in Q2, up from $41.2 million in Q2 of last year.
Dialysis patient access: Expanded from 40,000 patients in Q1 and Q2 to over 75,000 patients in Q3, with further expansion to 275,000 patients expected in Q4 through DaVita's operational pilot.
Medicare Advantage coverage: Significant number of Medicare Advantage plans are covering Vafseo, potentially doubling the addressable patient population.
Clinical trials: VOICE trial fully enrolled with over 2,100 patients; VOCAL study initiated with 350 patients to study red blood cell characteristics.
Prescription growth: 725 prescribers in Q2, up from 640 in Q1, with an average of 13.3 prescriptions per prescriber, an increase from 12 in Q1.
Nondialysis market expansion: Planning to initiate the VALOR trial for nondialysis patients by the end of the year, targeting a market potentially 4x to 5x larger than the dialysis market.
Financial position: Achieved $247,000 in net income in Q2, compared to a net loss of $8.6 million in Q2 last year, with $137.3 million in cash and cash equivalents.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access Challenges: Limited access to dialysis patients during the initial launch period, with only 40,000 patients having access in Q1 and Q2. Broader access to additional dialysis providers like DCI, IRC, and DaVita is still in progress, which could delay revenue growth.
Adherence and Dosing Issues: Adherence rates for Vafseo are consistent with the industry at 70%-80%, but some patients experienced hemoglobin drops when transitioning to the drug. This led to some patients reverting to prior treatments, impacting adoption rates.
Regulatory and Clinical Trial Risks: The VOICE trial, critical for post-TDAPA growth, will not complete until late 2026, with data available in early 2027. Any delays or negative outcomes could hinder the establishment of Vafseo as the standard of care.
Generic Competition for Auryxia: Auryxia lost IP exclusivity in March, and while no generics have been approved yet, the uncertainty around the timing of generic competition poses a risk to future revenue.
Economic and Pricing Pressures: The dialysis market has pricing complexities, especially in a post-TDAPA setting, which could impact the addressable market size and profitability.
Financial Risks: The company has a $7 million noncash expense related to warrant liability and $5.4 million in interest expenses, which could strain financial resources if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expansion of Patient Access for Vafseo: The company expects to increase patient access to Vafseo from 40,000 patients in Q1 and Q2 to over 75,000 patients in Q3, and further to at least 275,000 patients in Q4, driven by partnerships with dialysis providers such as DaVita, DCI, and IRC.
VOICE Trial Completion: The VOICE trial, which is an outcomes trial for Vafseo, is expected to complete in late 2026 with data available in early 2027. This trial aims to establish Vafseo as the standard of care by demonstrating potential superiority in clinical outcomes such as all-cause hospitalization.
VOCAL Study Initiation: The VOCAL study, focusing on dosing Vafseo three times a week, has been initiated and will enroll approximately 350 patients. A substudy will explore the impact of Vafseo on red blood cell characteristics, potentially demonstrating its physiological benefits.
VALOR Trial for Nondialysis Patients: The company plans to initiate the VALOR trial for nondialysis patients with anemia by the end of 2025, following discussions with the FDA. This trial targets a market potentially 4-5 times larger than the dialysis market.
Revenue Growth Expectations: The company anticipates significant revenue growth driven by increased patient access to Vafseo and continued strong performance of Auryxia. However, future Auryxia sales may be impacted by potential generic competition.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key metrics for patient segmentation in terms of home use and high ESA?
A:USRC's protocol allows PD use for both in-center and home patients, with 12% of total scripts for home patients and the remainder for in-center patients. With DaVita and others coming online, broad protocols will continue, potentially increasing home patient usage slightly. Medicare Advantage accounts for 20% of prescriptions, with 80% being Medicare fee-for-service. Growth in Medicare Advantage coverage is happening faster than expected.
Q:What is the current average dose strength for prescriptions?
A:Refill scripts show a 28% increase over the 300-milligram starting dose, with an average of 420 milligrams per script observed in clinical trials. Doses titrate up over time, with some providers allowing earlier titration at week 2.
Q:When will DaVita's operationalized protocol be implemented, and will other large dialysis organizations follow a similar process?
A:DaVita's pilot is expected to go live on the 18th of the month and last up to 3 months, with full network access by mid-November. Other large providers like Fresenius may follow a similar operational pilot process.
Q:What is the timeline for the Phase III trial design for VALOR and its potential label expansion?
A:The timeline depends on enrollment speed. The trial will involve 1,500 U.S. patients with an active comparator. Feasibility studies are ongoing to determine site and patient numbers. The goal is to enroll as quickly as possible.
Q:What is the outlook for Auryxia revenues and competitive dynamics?
A:Auryxia revenues grew due to increased access post-bundle implementation. Physicians are comfortable with its clinical profile. Only one authorized generic is currently on the market, and new generic competition could arise anytime. The company budgets conservatively, viewing any delay in competition as upside.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for the VALOR trial enrollment and the exact impact of new generic competition on Auryxia revenues, citing ongoing feasibility studies and conservative budgeting.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Carrasco Senior
Chief Officer
Conference
DCI IRC
ESAs
IRC dialysis
LLC Research
Mercedes Carrasco
Research Division
Senior VP
TDAPA VOICE
Type meeting
Vafseo dialysis
Vafseo standard
access Vafseo
access patient
access physician
adherence rate
blood cell
breadth depth
cause hospitalization
characteristic
color
comparator
completion
hemoglobin drop
launch Vafseo
lifespan
nondialysis
outcome
patient month
physician education
pilot
post TDAPA
prescribing access
AKBA Transcript
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call reveals a strong financial performance with a 15% YoY revenue increase and reduced net loss, indicating improved operational efficiency. Decreased R&D and operating expenses further enhance financial health. Despite the absence of strategic initiatives and forward-looking statements, the financial metrics suggest a positive market reaction. The lack of Q&A insights limits adjustment, but the financial performance alone supports a positive sentiment.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights strong financial performance with a 15% revenue increase and a 10% improvement in net loss, indicating operational efficiency. The positive cash position due to a successful equity raise and strategic initiatives in product development further enhance the outlook. Despite the risks associated with forward-looking statements, the overall sentiment is positive, suggesting a potential stock price increase in the short term.
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights significant patient access expansion for Vafseo, improved financial performance, and positive physician feedback on clinical data. Although there are operational challenges, strategies are in place to address them. The Q&A reveals enthusiasm for the product and progress in partnerships, despite some uncertainties. Overall, the company's optimistic revenue growth expectations, patient access expansion, and improved net income suggest a positive stock price movement over the next two weeks.
AKBA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
